Fate Therapeutics, Inc. develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cells product candidates.
Market Cap | 523.749 Million | Shares Outstanding | 97.17 Million | Avg 30-day Volume | 3.404 Million |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.86 |
Price to Revenue | 99.267 | Debt to Equity | 0.0 | EBITDA | -198.548 Million |
Price to Book Value | 8.1664 | Operating Margin | -388.55780000000004 | Enterprise Value | 4.827 Billion |
Current Ratio | 7.793 | EPS Growth | -0.067 | Quick Ratio | 7.684 |
1 Yr BETA | 1.7425 | 52-week High/Low | 43.12 / 4.02 | Profit Margin | -379.8858 |
Operating Cash Flow Growth | -315.1775 | Altman Z-Score | 12.5563 | Free Cash Flow to Firm | -118.688 Million |
Earnings Report | 2023-05-03 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
WOLCHKO J SCOTT PRESIDENT AND CEO |
|
0 | 2023-02-06 | 4 |
TAHL CINDY GENERAL COUNSEL AND SECRETARY |
|
0 | 2023-02-06 | 3 |
VALAMEHR BAHRAM CHIEF R&D OFFICER |
|
0 | 2023-02-06 | 5 |
DULAC EDWARD J III CHIEF FINANCIAL OFFICER |
|
0 | 2023-02-06 | 3 |
CHU YU-WAYE CHIEF MEDICAL OFFICER |
|
0 | 2023-02-06 | 3 |
POWL BRIAN T. CHIEF COMMERCIAL OFFICER |
|
0 | 2023-02-06 | 3 |
|
311,231 | 2023-01-19 | 4 | |
PLAVSIC MARK CHIEF TECHNICAL OFFICER |
|
123,705 | 2023-01-10 | 2 |
|
617,424 | 2022-06-09 | 1 | |
|
22,552 | 2022-06-09 | 2 | |
|
66,282 | 2022-06-09 | 2 | |
|
12,968,553 | 2022-06-09 | 1 | |
|
22,383 | 2022-06-09 | 4 | |
|
23,224 | 2022-06-09 | 1 | |
|
21,741 | 2022-06-09 | 2 | |
|
25,287 | 2022-06-09 | 1 | |
|
23,224 | 2021-06-09 | 0 | |
SHOEMAKER DANIEL D CHIEF SCIENTIFIC OFFICER |
|
73,020 | 2021-03-08 | 0 |
|
2,310,432 | 2019-07-31 | 0 | |
ABBOT STEWART CHIEF DEVELOPMENT OFFICER |
|
64,917 | 2018-05-15 | 0 |
STORGARD CHRIS CHIEF MEDICAL OFFICER |
|
0 | 2018-01-16 | 0 |
|
0 | 2017-05-02 | 0 | |
FATE THERAPEUTICS INC CHIEF SCIENTIFIC OFFICER |
|
103,816 | 2016-01-08 | 0 |
WEYER CHRISTIAN SEE REMARKS |
|
30,429 | 2015-04-13 | 0 |
MULTANI PRATIK S CHIEF MEDICAL OFFICER |
|
3,024 | 2015-01-05 | 0 |
FLYNN PETER D SEE REMARKS |
|
6,505 | 2015-01-05 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-02-07 16:15:19 -0500 | 2023-02-06 | A | 425,000 | a | 425,000 | direct | ||||||||||
2023-02-07 16:18:21 -0500 | 2023-02-06 | A | 425,000 | a | 425,000 | direct | ||||||||||
2023-02-07 16:16:46 -0500 | 2023-02-06 | A | 425,000 | a | 425,000 | direct | ||||||||||
2023-02-07 16:21:26 -0500 | 2023-02-06 | A | 500,000 | a | 500,000 | direct | ||||||||||
2023-02-07 16:20:09 -0500 | 2023-02-06 | A | 450,000 | a | 450,000 | direct | ||||||||||
2023-02-07 16:13:35 -0500 | 2023-02-06 | A | 425,000 | a | 425,000 | direct |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
FATE THERAPEUTICS INC FATE | 2023-03-24 22:15:03 UTC | 4.4119 | 0.4081 | 1400000 |
FATE THERAPEUTICS INC FATE | 2023-03-24 21:45:03 UTC | 4.4119 | 0.4081 | 1400000 |
FATE THERAPEUTICS INC FATE | 2023-03-24 21:15:03 UTC | 4.4119 | 0.4081 | 1400000 |
FATE THERAPEUTICS INC FATE | 2023-03-24 20:45:03 UTC | 4.4119 | 0.4081 | 1400000 |
FATE THERAPEUTICS INC FATE | 2023-03-24 20:15:04 UTC | 4.4119 | 0.4081 | 1400000 |
FATE THERAPEUTICS INC FATE | 2023-03-24 19:45:03 UTC | 4.4119 | 0.4081 | 1300000 |
FATE THERAPEUTICS INC FATE | 2023-03-24 19:15:04 UTC | 4.4119 | 0.4081 | 1300000 |
FATE THERAPEUTICS INC FATE | 2023-03-24 18:45:04 UTC | 4.4119 | 0.4081 | 1300000 |
FATE THERAPEUTICS INC FATE | 2023-03-24 18:15:03 UTC | 4.4119 | 0.4081 | 1300000 |
FATE THERAPEUTICS INC FATE | 2023-03-24 17:45:03 UTC | 4.4119 | 0.4081 | 1300000 |
FATE THERAPEUTICS INC FATE | 2023-03-24 17:15:03 UTC | 4.4119 | 0.4081 | 1300000 |
FATE THERAPEUTICS INC FATE | 2023-03-24 16:45:03 UTC | 4.4119 | 0.4081 | 1300000 |
FATE THERAPEUTICS INC FATE | 2023-03-24 16:15:03 UTC | 4.4119 | 0.4081 | 1300000 |
FATE THERAPEUTICS INC FATE | 2023-03-24 15:45:03 UTC | 4.4119 | 0.4081 | 1300000 |
FATE THERAPEUTICS INC FATE | 2023-03-24 15:15:03 UTC | 4.4119 | 0.4081 | 1300000 |
FATE THERAPEUTICS INC FATE | 2023-03-24 14:45:03 UTC | 4.1619 | 0.4081 | 1300000 |
FATE THERAPEUTICS INC FATE | 2023-03-24 14:15:03 UTC | 4.1619 | 0.4081 | 1300000 |
FATE THERAPEUTICS INC FATE | 2023-03-24 13:45:03 UTC | 4.1619 | 0.4081 | 1300000 |
FATE THERAPEUTICS INC FATE | 2023-03-24 13:15:04 UTC | 4.1619 | 0.4081 | 1300000 |
FATE THERAPEUTICS INC FATE | 2023-03-24 12:45:03 UTC | 4.1619 | 0.4081 | 1300000 |
Congress Person | Party | Chamber | Filing | Filing Date | Transaction Date | Security Type | Owner | Transaction | Amount | |
---|---|---|---|---|---|---|---|---|---|---|
Hon. Daniel Goldman | House | Filing | 2023-02-09 | 2023-01-31 | S | $1,001-$15,000 |